The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
|Articles|March 9, 2011
- December 2010
- Volume 4
- Issue 12
FDA Green-Lights Phase III Trial for Drug-Eluting Microspheres in Liver Cancer
Author(s)OBTN
The FDA has given Merit Medical Systems the green light for a phase III clinical trial investigating QuadraSphere Microspheres in patients with primary liver cancer.
Advertisement
The FDA has given Merit Medical Systems the green light for a phase III clinical trial investigating QuadraSphere Microspheres in patients with primary liver cancer. The drug-eluting microspheres release doxorubicin to the tumor and are approved for peripheral arteriovenous malformations and to embolize hypervascular tumors. The phase III study will take place in the United States and abroad, enrolling only those patients whose liver disease is localized and unresectable.
Articles in this issue
over 15 years ago
Medulloblastoma Subtypes Are Different Diseasesover 15 years ago
ASH 2010: Elotuzumab Highly Active in Patients With Advanced Myelomaover 15 years ago
FDA Requests Label Change for Generic Docetaxelover 15 years ago
FDA Considers Approval of Fusilev for Colorectal CancerAdvertisement
Related to this article
The FDA gave a CRL to the NDA seeking the approval of Orviglance for use in the detection of liver metastases in patients with severe kidney impairment.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The FDA has issued a CRL to LNTH-2501 for the localization of SSTR-positive NETs.
Advertisement
Advertisement
Trending on OncLive
1
TP53 Status and Time Toxicity Shape Sequencing Decisions in EGFR-Mutated NSCLC
2
Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase 3 NSCLC Trial
3
Savolitinib Gains NMPA Approval for MET-Amplified Gastric and GEJ Adenocarcinoma
4
Rusfertide Maintains Long-Term Thromboembolism Control in Phlebotomy-Dependent Polycythemia Vera
5